GO:0002162 dystroglycan binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002162 dystroglycan binding is a molecular function defined as binding to dystroglycan, a glycoprotein found in muscle and non-muscle tissues that is often associated with dystrophin.
• Dystroglycan is cleaved into two non-covalently associated subunits, alpha-dystroglycan and beta-dystroglycan, which mediate distinct binding interactions.
• Alpha-dystroglycan binds extracellular matrix proteins such as laminin through its LARGE glycans, while beta-dystroglycan anchors the complex to the cell membrane.
• Dystroglycan binding is critical for sarcolemmal integrity, and defects in this function are linked to muscular dystrophies and cardiac dysfunction.
• In the brain, dystroglycan binding to alpha-neurexin competes with neurexophilin-1 and neuroligin, influencing synaptic organization.
• Research on dystroglycan binding employs knockout, point-mutation, knock-in, and overexpression models, along with binding assays and structural studies.
Description
Dystroglycan binding (GO:0002162) is a molecular function that describes the selective interaction of a protein or other molecule with dystroglycan, a central glycoprotein of the dystrophin-glycoprotein complex. Dystroglycan is expressed in a wide range of tissues, including skeletal muscle, heart, and brain, where it links the extracellular matrix to the cytoskeleton and participates in signaling. The dystroglycan protein is post-translationally cleaved into two subunits: alpha-dystroglycan, which is highly glycosylated and binds extracellular ligands, and beta-dystroglycan, which spans the membrane and interacts with dystrophin and other intracellular proteins. This molecular function is essential for maintaining muscle cell stability and for proper neuronal development. Researchers study dystroglycan binding to understand muscular dystrophies, cardiac disorders, and brain function, as well as to develop targeted therapies.
dystroglycan binding At A Glance
| GO ID | GO:0002162 |
|---|---|
| GO term | dystroglycan binding |
| Ontology | molecular_function |
| Synonym | alpha-dystroglycan binding, beta-dystroglycan binding |
| Major function | Binding to dystroglycan, a glycoprotein found in muscle and non-muscle tissues, often in association with dystrophin. |
| Definition source | QuickGO |
| Subunits | alpha-dystroglycan (N-terminal) and beta-dystroglycan (C-terminal), non-covalently associated. |
| Related complex | Dystrophin-glycoprotein complex (DGC) |
| Tissue distribution | Muscle and non-muscle tissues, including brain. |
What Is GO:0002162?
Dystroglycan binding is the molecular function of selectively interacting with dystroglycan, a glycoprotein that is present in non-muscle tissues as well as in muscle tissues and is often found in association with dystrophin. The native dystroglycan is cleaved into two non-covalently associated subunits: alpha (N-terminal) and beta (C-terminal). This binding can occur with either subunit, as reflected by the synonyms alpha-dystroglycan binding and beta-dystroglycan binding.
Why Is dystroglycan binding Important in Cell Biology?
Dystroglycan binding is fundamental for tissue integrity and signaling because dystroglycan serves as a molecular bridge between the extracellular matrix and the intracellular cytoskeleton. Disruption of this binding function leads to a range of pathologies, including congenital muscular dystrophies, cardiomyopathy, and synaptic abnormalities. Understanding the molecular details of dystroglycan binding is therefore crucial for developing therapeutic strategies that target these interactions, such as peptide-based muscle targeting or modulation of glycosylation.
• Maintains sarcolemmal stability by linking laminin in the extracellular matrix to dystrophin inside muscle cells.
• Defects in dystroglycan binding cause muscular dystrophies, including Duchenne muscular dystrophy and limb-girdle muscular dystrophies.
• Matriglycan on alpha-dystroglycan is required for t-tubule structural integrity in cardiac muscle, linking binding to heart function.
• In the brain, dystroglycan binding to alpha-neurexin regulates synaptic organization and competes with other synaptic proteins.
• Dystroglycan binding is exploited for targeted drug delivery, e.g., A2G80-modified liposomes for muscle targeting.
• Structural studies of laminin binding to LARGE glycans on dystroglycan inform the design of glycan-based therapeutics.
• Beta-dystroglycan binding epitopes within alpha-dystroglycan are critical for subunit association and complex assembly.
• Sarcospan increases laminin-binding capacity of alpha-dystroglycan, offering a therapeutic strategy independent of Galgt2.
• Dystroglycan binding is essential for early embryonic development, as knockout of dystroglycan is lethal in mice.
• Research on dystroglycan binding aids in understanding cancer metastasis, where dystroglycan expression is often altered.
Molecular Mechanism of dystroglycan binding
Substrate recognition and glycosylation-dependent binding
In simple terms: Dystroglycan must be properly glycosylated to bind its partners.
Alpha-dystroglycan undergoes extensive O-mannosyl glycosylation, producing a unique glycan structure called matriglycan that is essential for binding to laminin and other extracellular matrix proteins. The LARGE glycans on dystroglycan form a structural platform that directly interacts with laminin G domains, as revealed by crystallographic studies. This glycosylation-dependent binding is critical for muscle function, and defects in glycosylation lead to dystroglycanopathies.
Alpha-dystroglycan and beta-dystroglycan subunit interactions
In simple terms: The two parts of dystroglycan stick together but have different jobs.
The native dystroglycan is cleaved into alpha- and beta-subunits that remain non-covalently associated. Alpha-dystroglycan is entirely extracellular and binds ligands such as laminin, while beta-dystroglycan spans the membrane and binds dystrophin intracellularly. The beta-dystroglycan binding epitope within the C-terminal region of alpha-dystroglycan has been mapped, revealing key residues required for subunit association.
Competitive binding in the brain
In simple terms: In the brain, dystroglycan chooses between different binding partners.
Dystroglycan binding to alpha-neurexin competes with neurexophilin-1 and neuroligin, indicating a regulatory mechanism that may influence synapse formation and function. This competition suggests that dystroglycan binding is not static but can be modulated by the availability of alternative ligands, which is important for neuronal development.
Structural basis of laminin binding
In simple terms: The shape of the sugar chains on dystroglycan determines how it grabs laminin.
Structural analysis of laminin binding to LARGE glycans on dystroglycan has elucidated the molecular details of this interaction, showing that the glycans form a specific binding surface. This structural knowledge is being used to design therapies that enhance or mimic dystroglycan binding, such as sarcospan, which increases laminin-binding capacity.
Key Genes Involved in GO:0002162 dystroglycan binding
The following genes and proteins are central to dystroglycan binding and its biological context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DAG1 | Encodes dystroglycan, the protein that is cleaved into alpha- and beta-subunits | Mutations cause muscular dystrophy and brain abnormalities; key target for knockout and knock-in models |
| LAMA2 | Encodes laminin alpha-2 chain, a major extracellular ligand for alpha-dystroglycan | Defects cause congenital muscular dystrophy; used to study binding specificity |
| LARGE1 | Glycosyltransferase that adds LARGE glycans to alpha-dystroglycan | Overexpression enhances laminin binding and ameliorates dystrophy in models |
| POMT1 | O-mannosyltransferase initiating glycosylation of alpha-dystroglycan | Mutations cause Walker-Warburg syndrome; used to study glycosylation-dependent binding |
| POMT2 | Partner of POMT1 in O-mannosylation | Similar to POMT1, defects lead to dystroglycanopathies |
| FKRP | Glycosyltransferase involved in matriglycan synthesis | Mutations cause limb-girdle muscular dystrophy; models show reduced laminin binding |
| POMGNT1 | O-mannose beta-1,2-N-acetylglucosaminyltransferase | Defects cause muscle-eye-brain disease; affects dystroglycan binding |
| POMGNT2 | Glycosyltransferase in O-mannosyl glycan synthesis | Mutations linked to muscular dystrophy; studied via knockout |
| B3GALNT2 | Beta-1,3-N-acetylgalactosaminyltransferase | Involved in matriglycan synthesis; mutations cause dystroglycanopathy |
| B4GAT1 | Beta-1,4-glucuronyltransferase | Required for LARGE glycan formation; knockout reduces binding |
| DAG1 (beta-subunit) | Binds dystrophin and intracellular proteins | Studied for its role in membrane anchoring and signaling |
| DMD | Encodes dystrophin, which binds beta-dystroglycan | Mutations cause Duchenne muscular dystrophy; models used to study complex stability |
| UTRN | Encodes utrophin, a dystrophin homolog that binds beta-dystroglycan | Upregulation compensates for dystrophin loss; studied in overexpression models |
| SSPN | Encodes sarcospan, which increases laminin-binding capacity of alpha-dystroglycan | Overexpression ameliorates DMD in mice independent of Galgt2 |
| NRXN1 | Encodes alpha-neurexin, a brain-specific binding partner of dystroglycan | Competes with neuroligin; studied in synaptic models |
| NRXN2 | Another neurexin isoform that binds dystroglycan | Similar to NRXN1; involved in synaptic organization |
| NLGN1 | Encodes neuroligin-1, which competes with dystroglycan for neurexin binding | Used to study competitive binding in brain |
| NXPH1 | Encodes neurexophilin-1, a competitor of dystroglycan binding to neurexin | Modulates synaptic binding; studied in knockout models |
How Is dystroglycan binding Regulated?
Dystroglycan binding is regulated at multiple levels, including glycosylation of alpha-dystroglycan by a series of glycosyltransferases such as POMT1, POMT2, FKRP, and LARGE1. The extent of glycosylation directly determines binding affinity for laminin and other ligands. Additionally, competitive interactions with proteins like neurexophilin-1 and neuroligin can modulate dystroglycan binding in the brain. Sarcospan has been shown to increase the laminin-binding capacity of alpha-dystroglycan, providing a regulatory mechanism independent of Galgt2. Furthermore, the expression levels of dystroglycan itself and its binding partners can influence the overall binding activity.
dystroglycan binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DAG1 | Muscular dystrophy, brain abnormalities | Knockout mouse, point-mutation knock-in |
| POMT1 | Walker-Warburg syndrome | Patient-derived iPSCs, knockout zebrafish |
| FKRP | Limb-girdle muscular dystrophy | Knock-in mouse models |
| SSPN | Duchenne muscular dystrophy (amelioration) | Overexpression transgenic mouse |
| LARGE1 | Dystroglycanopathy | Overexpression in cell culture and mouse models |
Muscular dystrophies
Defects in dystroglycan binding due to mutations in glycosyltransferases or dystroglycan itself cause a group of disorders known as dystroglycanopathies, which include Walker-Warburg syndrome, muscle-eye-brain disease, and limb-girdle muscular dystrophy. These conditions are characterized by progressive muscle weakness and often involve brain and eye abnormalities. In Duchenne muscular dystrophy, the absence of dystrophin destabilizes the dystrophin-glycoprotein complex, leading to reduced dystroglycan binding and sarcolemmal damage. Sarcospan overexpression has been shown to increase laminin-binding capacity and ameliorate disease in DMD models.
Cardiac dysfunction
Matriglycan on alpha-dystroglycan is essential for maintaining t-tubule structural integrity in cardiac muscle, and loss of this glycan leads to cardiomyopathy. Dystroglycan binding to laminin in the heart is critical for mechanotransduction and electrical coupling, and disruptions contribute to heart failure.
Neurological disorders
In the brain, dystroglycan binding to alpha-neurexin is important for synaptic organization, and competition with neurexophilin-1 and neuroligin modulates this interaction. Abnormal dystroglycan binding has been implicated in neuronal migration disorders and cognitive deficits associated with dystroglycanopathies.
From dystroglycan binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of dystroglycan loss on muscle integrity? | DAG1 knockout mouse or CRISPR knockout in C2C12 myoblasts |
| How do specific point mutations in DAG1 affect ligand binding? | Point-mutation knock-in via CRISPR in cell lines |
| Can overexpression of LARGE enhance dystroglycan binding? | LARGE1 overexpression in muscle cells or transgenic mice |
| What is the role of beta-dystroglycan binding epitope? | Knock-in of tagged beta-dystroglycan for interaction studies |
| How does sarcospan increase laminin binding? | SSPN overexpression in DMD mouse models |
| What is the impact of dystroglycan binding on synaptic function? | Conditional knockout in neurons or brain organoids |
How to Study the dystroglycan binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance (SPR) | Binding affinity and kinetics | Measure interaction between dystroglycan and laminin |
| Lectin blotting | Glycosylation status of alpha-dystroglycan | Assess matriglycan levels in cells and tissues |
| Immunofluorescence | Localization of dystroglycan and binding partners | Study sarcolemmal integrity and synaptic localization |
| X-ray crystallography | Three-dimensional structure of binding interface | Elucidate laminin-LARGE glycan interaction |
| CRISPR knockout | Loss-of-function effects | Determine role of DAG1 in muscle and brain |
| Knock-in of point mutations | Effect of specific residues on binding | Map beta-dystroglycan binding epitope |
| Overexpression | Gain-of-function effects | Test sarcospan or LARGE as therapeutics |
| Competition assays | Relative binding affinities | Study neurexin-dystroglycan interactions in brain |
Binding assays
Solid-phase binding assays, surface plasmon resonance (SPR), and isothermal titration calorimetry (ITC) are used to measure the affinity and kinetics of dystroglycan binding to ligands such as laminin. These methods require purified recombinant dystroglycan or its subunits, often produced in mammalian cells to ensure proper glycosylation.
Glycosylation analysis
Mass spectrometry and lectin blotting are employed to characterize the glycosylation status of alpha-dystroglycan, which is critical for its binding function. Antibodies like IIH6 specifically recognize the glycosylated form of alpha-dystroglycan and are used in immunoblots and immunofluorescence.
Structural biology
X-ray crystallography and cryo-electron microscopy have been used to solve the structure of dystroglycan in complex with laminin or other ligands, revealing the molecular basis of binding. These studies inform the design of therapeutics that mimic or enhance binding.
Genetic models
CRISPR/Cas9-mediated knockout, knock-in, and point mutations in DAG1 or glycosyltransferase genes are used to study the consequences of altered dystroglycan binding in cell culture and animal models. Overexpression of sarcospan or LARGE is used to test therapeutic strategies.
How CRISPR Can Be Used to Study GO:0002162 dystroglycan binding
Knockout
CRISPR/Cas9 knockout of DAG1 or glycosyltransferase genes such as POMT1, FKRP, and LARGE1 is used to eliminate dystroglycan binding and study downstream effects on muscle and brain development. These models recapitulate key features of dystroglycanopathies and are valuable for testing therapeutic interventions.
Point Mutation
Point mutations in DAG1 that disrupt specific binding interfaces, such as the beta-dystroglycan binding epitope, can be introduced via CRISPR to dissect the contribution of individual residues to ligand binding and complex assembly. Such models help distinguish between binding to alpha- versus beta-dystroglycan.
Knock-in
Knock-in of tagged dystroglycan (e.g., GFP or HA) allows for real-time imaging and pull-down of binding partners in native tissues. Knock-in of disease-associated mutations, such as those found in dystroglycanopathies, provides accurate models for studying altered binding.
Overexpression
Overexpression of LARGE1 or SSPN via CRISPR activation or transgenic delivery increases dystroglycan binding to laminin and ameliorates muscle pathology in DMD models. Overexpression models are also used to study competitive binding in the brain.
How EDITGENE Supports dystroglycan binding Research
Researchers studying dystroglycan binding-related genes often need to determine whether a candidate gene is causally involved in the binding process or in disease pathogenesis. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell and animal models, enabling functional validation of genes implicated in dystroglycan binding and its associated disorders.
Contact EDITGENE today to design your custom CRISPR model for dystroglycan binding research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| DAG1 Knockout HeLa Cell Line | EDJ-KQ29 | Human | 1605 | Details Get a Quote |
| PLEC Knockout HEK293 Cell Line | EDJ-KQ1931 | Human | 5339 | Details Get a Quote |
| VCL Knockout HEK293 Cell Line | EDJ-KQ2846 | Human | 7414 | Details Get a Quote |
| DMD Knockout HEK293 Cell Line | EDJ-KQ3154 | Human | 1756 | Details Get a Quote |
| MAP2 Knockout HEK293 Cell Line | EDJ-KQ3258 | Human | 4133 | Details Get a Quote |
| DAG1 Knockout HEK293 Cell Line | EDJ-KQ3800 | Human | 1605 | Details Get a Quote |
| AGRN Knockout HEK293 Cell Line | EDJ-KQ4025 | Human | 375790 | Details Get a Quote |
| SNTA1 Knockout HEK293 Cell Line | EDJ-KQ5814 | Human | 6640 | Details Get a Quote |
| LARGE2 Knockout HEK293 Cell Line | EDJ-KQ7655 | Human | 120071 | Details Get a Quote |
| CLASP2 Knockout HEK293 Cell Line | EDJ-KQ7838 | Human | 23122 | Details Get a Quote |
| AGR2 Knockout HEK293 Cell Line | EDJ-KQ12312 | Human | 10551 | Details Get a Quote |
| AGR3 Knockout HEK293 Cell Line | EDJ-KQ12313 | Human | 155465 | Details Get a Quote |
| CLASP1 Knockout HEK293 Cell Line | EDJ-KQ12929 | Human | 23332 | Details Get a Quote |
| AGR2 Knockout A-549 Cell Line | EDJ-KQ24936 | Human | 10551 | Details Get a Quote |
| LARGE2 Knockout A-549 Cell Line | EDJ-KQ33011 | Human | 120071 | Details Get a Quote |
Displaying Records 1 To 15 Of 49 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About dystroglycan binding
What is dystroglycan binding?
Dystroglycan binding is a molecular function (GO:0002162) that describes the selective interaction with dystroglycan, a glycoprotein found in muscle and non-muscle tissues, often in association with dystrophin.
What genes are involved in dystroglycan binding?
Key genes include DAG1 (encoding dystroglycan), LAMA2 (laminin), LARGE1, POMT1, POMT2, FKRP, and others involved in glycosylation of alpha-dystroglycan.
What are the subunits of dystroglycan?
Dystroglycan is cleaved into alpha-dystroglycan (N-terminal) and beta-dystroglycan (C-terminal), which are non-covalently associated.
How does dystroglycan binding relate to muscular dystrophy?
Defects in dystroglycan binding due to mutations in glycosyltransferases or dystroglycan cause dystroglycanopathies, including Walker-Warburg syndrome and limb-girdle muscular dystrophy.
What is the role of alpha-dystroglycan in binding?
Alpha-dystroglycan is highly glycosylated and binds extracellular matrix proteins such as laminin through its LARGE glycans.
How is dystroglycan binding studied in the lab?
Common methods include surface plasmon resonance, lectin blotting, immunofluorescence, X-ray crystallography, and CRISPR-based genetic models.
What is the beta-dystroglycan binding epitope?
The beta-dystroglycan binding epitope is a region within the C-terminal part of alpha-dystroglycan that mediates non-covalent association between the two subunits.
Can dystroglycan binding be targeted therapeutically?
Yes, strategies such as overexpression of sarcospan or LARGE1 enhance laminin binding and ameliorate disease in models of Duchenne muscular dystrophy.
What is the role of dystroglycan binding in the brain?
In the brain, dystroglycan binds alpha-neurexin and competes with neurexophilin-1 and neuroligin, influencing synaptic organization.
How does matriglycan affect dystroglycan binding?
Matriglycan is a glycosylation structure on alpha-dystroglycan that is essential for binding to laminin and for maintaining t-tubule integrity in cardiac muscle.
Conclusion
Dystroglycan binding (GO:0002162) is a fundamental molecular function that connects the extracellular matrix to the cytoskeleton and is essential for muscle, heart, and brain physiology. Disruption of this binding leads to severe diseases, including muscular dystrophies and cardiac dysfunction. Ongoing research using CRISPR models and structural biology continues to unravel the precise mechanisms of dystroglycan binding and to develop targeted therapies. EDITGENE supports these efforts with custom CRISPR services to accelerate discoveries in this field.
References
- 1. Mamsa H et al.. 2022. Sarcospan increases laminin-binding capacity of α-dystroglycan to ameliorate DMD independent of Galgt2.. Hum Mol Genet 31(5):718-732 PMID: 34581784
- 2. Martin PT. 2003. Dystroglycan glycosylation and its role in matrix binding in skeletal muscle.. Glycobiology 13(8):55R-66R PMID: 12736199
- 3. Wan L et al.. 2025. Structure and assembly of the dystrophin glycoprotein complex.. Nature 637(8048):1252-1260 PMID: 39663450
- 4. Sasaki E et al.. 2021. Alpha-dystroglycan binding peptide A2G80-modified stealth liposomes as a muscle-targeting carrier for Duchenne muscular dystrophy.. J Control Release 329:1037-1045 PMID: 33080271
- 5. Briggs DC et al.. 2016. Structural basis of laminin binding to the LARGE glycans on dystroglycan.. Nat Chem Biol 12(10):810-4 PMID: 27526028
- 6. Sciandra F et al.. 2001. Identification of the beta-dystroglycan binding epitope within the C-terminal region of alpha-dystroglycan.. Eur J Biochem 268(16):4590-7 PMID: 11502221
- 7. Hord JM et al.. 2024. Matriglycan maintains t-tubule structural integrity in cardiac muscle.. Proc Natl Acad Sci U S A 121(22):e2402890121 PMID: 38771868
- 8. Reissner C et al.. 2014. Dystroglycan binding to α-neurexin competes with neurexophilin-1 and neuroligin in the brain.. J Biol Chem 289(40):27585-603 PMID: 25157101
